These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8452352)

  • 41. The pharmacokinetics of meropenem in volunteers.
    Bax RP; Bastain W; Featherstone A; Wilkinson DM; Hutchison M; Haworth SJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():311-20. PubMed ID: 2808215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of zileuton and its metabolites in patients with renal impairment.
    Awni WM; Wong S; Chu SY; Patterson K; Hansen R; Machinist JM; Drajesk J; Keane WF; Halstenson CE
    J Clin Pharmacol; 1997 May; 37(5):395-404. PubMed ID: 9156372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
    Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma pharmacokinetics and urine concentrations of meropenem in ewes.
    Abo El Sooud K
    J Vet Pharmacol Ther; 2004 Feb; 27(1):27-30. PubMed ID: 14995963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
    Kneer J; Tam YK; Blouin RA; Frey FJ; Keller E; Stathakis C; Luginbuehl B; Stoeckel K
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1952-7. PubMed ID: 2610506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.
    Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.
    Kielstein JT; Czock D; Schöpke T; Hafer C; Bode-Böger SM; Kuse E; Keller F; Fliser D
    Crit Care Med; 2006 Jan; 34(1):51-6. PubMed ID: 16374156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disposition of famotidine in renal insufficiency.
    Halstenson CE; Abraham PA; Opsahl JA; Chremos AN; Keane WF; Matzke GR
    J Clin Pharmacol; 1987 Oct; 27(10):782-7. PubMed ID: 3429684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease.
    Krishnaswami S; Chow V; Boy M; Wang C; Chan G
    J Clin Pharmacol; 2014 Jan; 54(1):46-52. PubMed ID: 24030917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
    Jaruratanasirikul S; Sriwiriyajan S
    J Antimicrob Chemother; 2003 Sep; 52(3):518-21. PubMed ID: 12917242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of ceftazidime in patients with renal insufficiency.
    Welage LS; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1984 Feb; 25(2):201-4. PubMed ID: 6370127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of fluconazole in renal failure.
    Berl T; Wilner KD; Gardner M; Hansen RA; Farmer B; Baris BA; Henrich WL
    J Am Soc Nephrol; 1995 Aug; 6(2):242-7. PubMed ID: 7579091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral flecainide pharmacokinetics in patients with impaired renal function.
    Forland SC; Burgess E; Blair AD; Cutler RE; Kvam DC; Weeks CE; Fox JM; Conard GJ
    J Clin Pharmacol; 1988 Mar; 28(3):259-67. PubMed ID: 3129455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.
    Thalhammer F; Hörl WH
    Clin Pharmacokinet; 2000 Oct; 39(4):271-9. PubMed ID: 11069213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.
    Halstenson CE; Guay DR; Opsahl JA; Hirata CA; Olanoff LS; Novak E; Ko H; Cathcart KS; Matzke GR
    Antimicrob Agents Chemother; 1990 Apr; 34(4):519-23. PubMed ID: 2344159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
    Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
    Isla A; Maynar J; Sánchez-Izquierdo JA; Gascón AR; Arzuaga A; Corral E; Pedraz JL
    J Clin Pharmacol; 2005 Nov; 45(11):1294-304. PubMed ID: 16239363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
    Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
    Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.